Compare PSN & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | BLTE |
|---|---|---|
| Founded | 1944 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.6B |
| IPO Year | 2019 | 2021 |
| Metric | PSN | BLTE |
|---|---|---|
| Price | $49.61 | $154.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $79.18 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.1M | 104.3K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.77 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $6,364,245,000.00 | N/A |
| Revenue This Year | $5.87 | N/A |
| Revenue Next Year | $7.61 | $492.11 |
| P/E Ratio | $102.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.38 | $56.68 |
| 52 Week High | $89.50 | $200.00 |
| Indicator | PSN | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 40.61 |
| Support Level | $49.38 | $148.06 |
| Resistance Level | $66.57 | $161.28 |
| Average True Range (ATR) | 2.27 | 6.20 |
| MACD | -0.30 | -1.18 |
| Stochastic Oscillator | 3.95 | 3.36 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.